RxDoctor Payments Data

Yu-Ping Wang

Cardiovascular Disease · Stanford, CANPI 1275717761

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $59,953 of the $79,127 with a category attached, or 75.8%. 9 manufacturers reported payments, led by AstraZeneca at 26.7% of the total. Reporting peaked in 2021 at $29,720 and has fallen 99.7% since, to $77 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,127in general payments, 2019–2025

Across 62 payments — averaging $1276.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$21K
  • Artivion, Inc.$20K
  • Novartis$18K
  • CSL Behring$10K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Bio Products Laboratory USA, Inc.$3K
  • plus $2K from 3 others
$3,702,748in research payments, 2019–2025

Across 24 payments — averaging $154,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Artivion, Inc.$3.2M
  • AstraZeneca$295K
  • Regeneron$162K
  • Boston Scientific$44K
  • Novo Nordisk AS$11K

What the payments were for

  • Consulting fees$59,95376%
  • Speaking & faculty fees$14,44118%
  • Travel & lodging$3,4944%
  • Food & beverage$1,1441%
  • Education$950%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca20$21,162
Artivion, Inc.18$19,621
Novartis7$17,717
CSL Behring3$10,435
E.r. Squibb & Sons, L.L.C.4$5,273
Bio Products Laboratory USA, Inc.2$2,750
Regeneron3$1,878
Johnson & Johnson(2 entities)2$214
LEO Pharma Inc.3$77

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,127 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Other cardiovascular disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →